Reproductive Endocrinology Ovarian Hormones

Progestogen Hypersensitivity

Chiarella SE, Buchheit KM, Foer D

Published December 2023 The journal of allergy and clinical immunology. In practice, 11(12), 3606-3613.e2
DOI 10.1016/j.jaip.2023.07.050 PMID 37579875 PMC PMC10841326

RRM Academy Synopsis

Progestogen hypersensitivity is diagnosed mainly from symptom timing

A 2023 expert review of case reports and small case series says diagnosis of progestogen hypersensitivity rests mainly on symptom timing after hormone exposure. Symptoms range from rashes to airway spasm and anaphylaxis. The authors stopped using skin tests to diagnose it, because they judge the tests unreliable.

Key Findings

  • For 58% of women with progestogen hypersensitivity, an exogenous progestogen caused the first symptoms, such as a contraceptive progestin or progesterone given during in vitro fertilization treatment.
  • In the endogenous form, symptoms appear during the luteal phase, usually 3 – 10 days before menses, and ease once menses begin or ovulation is inhibited.
  • A positive progesterone skin test occurred in 50% of patients with the condition, and 6 out of 17 patients with suspected progestogen hypersensitivity had high progesterone-specific IgE levels.
  • Across 39 patients reviewed, biopsy found a perivascular inflammatory infiltrate in 72% of cases and a non-specific inflammatory infiltrate in 31%.
  • The authors report that no validated patient-reported outcome tools exist for tracking symptom control.

Interpretation

The paper is an expert review built on case reports, small case series and the authors' opinion. The authors split the condition into three types: from the body itself, from a drug, or both. Their criteria weigh symptoms, other causes, timing and response to ovulation inhibitors, so diagnosis rests mainly on dating symptoms against hormone exposure. They favor a progestogen challenge when confirmation is needed and safe, and they say the criteria still need validation.

RRM Context

The review bases diagnosis on clinical history, including whether symptoms fall in the luteal phase of the menstrual cycle in the endogenous form. Cycle charting, used in NaProTechnology and other fertility awareness-based methods, gives a dated record of where the luteal phase falls in a woman's own cycle. The authors say symptom timing in irregular cycles needs more research.

Abstract

Progestogen hypersensitivity (PH) is a heterogeneous disease characterized by diverse cutaneous manifestations, bronchospasm, and/or anaphylaxis. Possible triggers include ovarian progesterone and exogenous progestogens. The timing of symptoms is critical to diagnose PH: during the luteal phase of the menstrual cycle for the endogenous form and after exposure to progestins for exogenous PH. Diagnostic modalities such as progesterone skin testing have low sensitivity and specificity for PH. When exogenous PH is suspected, the allergist should consider a progestogen challenge. Treatment strategies should be tailored for each patient, including symptom-directed therapies, ovulation suppression, and progesterone desensitization. Future studies should explore the mechanisms of PH, validation of diagnostic criteria, and standardization of treatment strategies.

Topics

Related research

Reproductive Endocrinology › Ovarian Hormones › Progesterone
Sergio E Chiarella, Kathleen M Buchheit, Dinah Foer
S Chiarella, K Buchheit, D Foer
PMID 37579875 37579875 DOI 10.1016/j.jaip.2023.07.050 10.1016/j.jaip.2023.07.050 Chiarella et al. 2023, Chiarella 2023